Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in EuropeGlobeNewsWire • 05/28/25
Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq StockholmGlobeNewsWire • 05/16/25
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq StockholmGlobeNewsWire • 05/08/25
Alvotech Reports Results for the First Quarter of 2025 and Provides Business UpdateGlobeNewsWire • 05/07/25
Alvotech Reports Results for the First Quarter of 2025 and Provides Business UpdateGlobeNewsWire • 05/07/25
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025GlobeNewsWire • 05/07/25
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)GlobeNewsWire • 05/02/25
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDTGlobeNewsWire • 05/02/25
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)GlobeNewsWire • 03/26/25
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)GlobeNewsWire • 03/26/25
Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and ProductionGlobeNewsWire • 03/20/25
Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and ProductionGlobeNewsWire • 03/20/25
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for ReviewZacks Investment Research • 03/19/25
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, FloridaGlobeNewsWire • 03/07/25